bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary figures with legends from CCR5+ Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions
Authors: Blattner Carolin , Fleming Viktor , Weber Rebekka , Himmelhan Bianca , Altevogt Peter , Gebhardt Christoffer , Schulze Torsten J. , Razon Hila , Hawila Elias , Wildbaum Gizi , Utikal Jochen , Karin Nathan , Umansky Viktor
Published: March 2023

Fig.S1:CCR5 ligands are enriched in mouse melanoma lesions and induce the migration of CD11b Gr1 cells. Fig.S2:Immunosuppressivephenotype of CCR5 MDSC in tumor bearing mice. Fig.S3:Induction of CCR5 expression and immunosuppressive molecules by inflammatory factors. Fig.S4:Immunosuppressivepattern of CCR5 MDSC from melanoma patients. Fig.S5:Increased production of immunosuppressive molecules by CCR5 MDSC in melanoma patients.
Table S2 from microRNA-1246 Is an Exosomal Biomarker for Aggressive Prostate Cancer
Authors: Bhagirath Divya , Yang Thao Ly , Bucay Nathan , Sekhon Kirandeep , Majid Shahana , Shahryari Varahram , Dahiya Rajvir , Tanaka Yuichiro , Saini Sharanjot
Published: March 2023

Table S2 Significant differentially expressed miRNAs in aggressive PCa
Table S1 from microRNA-1246 Is an Exosomal Biomarker for Aggressive Prostate Cancer
Authors: Bhagirath Divya , Yang Thao Ly , Bucay Nathan , Sekhon Kirandeep , Majid Shahana , Shahryari Varahram , Dahiya Rajvir , Tanaka Yuichiro , Saini Sharanjot
Published: March 2023

List of microRNAs significantly dysregulated in A. BPH vs aggressive PCa B. normal vs aggressive PCa
Supplementary Table and Figures from NR1D1 Recruitment to Sites of DNA Damage Inhibits Repair and Is Associated with Chemosensitivity of Breast Cancer
Authors: Ka Na-Lee , Na Tae-Young , Na Hyelin , Lee Min-Ho , Park Han-Su , Hwang Sewon , Kim Il Yong , Seong Je Kyung , Lee Mi-Ock
Published: March 2023

This file contains 1 table (Supplementary Table S1) and 8 figures (Supplementary Fig. S1-8). Supplementary Table S1 shows the sequences of qRT-PCR primers and shRNAs; Supplementary Fig. S1 shows the expression of exogenously introduced NR1D1 in MCF7 cells as control; Supplementary Fig. S2 indicates that DNA repair is impaired in the presence of NR1D1; Supplementary Fig. S3 shows the interaction of NR1D1 and PARP1; Supplementary Fig. S4 shows that PARylation of NR1D1 is essential for its recruitment to DNA breakage sites; Supplementary Fig. S5 indicates that NR1D1 inhibits the recruitment the DNA damage response factors to the DNA breakage sites; Supplementary Fig. S6 highlights that NR1D1 and its ligand, GSK4112, increase the sensitivity of breast cancer cells to doxorubicin; Supplementary Fig. S7 shows immunohistochemistry staining for γH2AX in tumor sections; Supplementary Fig. S8 indicates that expression level of NR1D1 was higher in pCR group of breast cancer.
Supplementary Data from microRNA-1246 Is an Exosomal Biomarker for Aggressive Prostate Cancer
Authors: Bhagirath Divya , Yang Thao Ly , Bucay Nathan , Sekhon Kirandeep , Majid Shahana , Shahryari Varahram , Dahiya Rajvir , Tanaka Yuichiro , Saini Sharanjot
Published: March 2023

Includes supplemental methods, figure and table legends
Supplemental Figures S1-S4 from microRNA-1246 Is an Exosomal Biomarker for Aggressive Prostate Cancer
Authors: Bhagirath Divya , Yang Thao Ly , Bucay Nathan , Sekhon Kirandeep , Majid Shahana , Shahryari Varahram , Dahiya Rajvir , Tanaka Yuichiro , Saini Sharanjot
Published: March 2023

Merged file with following figues: Fig. S1 Characterization of serum exosomal preparations Fig. S2 Biological pathways potentially influenced by dysregulated miRNAsin aggressive PCa as compared to BPH Fig. S3 Exosomal miR-1246 expression patterns differ from circulating miR-1246 expression in sera of prostate cancer patients Fig. S4 ex-miR-1246 expression as a measure of PCa aggressiveness
Figure S6 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Authors: Byrd Tiara T. , Fousek Kristen , Pignata Antonella , Szot Christopher , Samaha Heba , Seaman Steven , Dobrolecki Lacey , Salsman Vita S. , Oo Htoo Zarni , Bielamowicz Kevin , Landi Daniel , Rainusso Nino , Hicks John , Powell Suzanne , Baker Matthew L. , Wels Winfried S. , Koch Joachim , Sorensen Poul H. , Deneen Benjamin , Ellis Matthew J. , Lewis Michael T. , Hegde Meenakshi , Fletcher Bradley S. , St. Croix Brad , Ahmed Nabil
Published: March 2023

Mice that received systemic administration of L2 CAR T cells have normal pathology.
Figure S4 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Authors: Byrd Tiara T. , Fousek Kristen , Pignata Antonella , Szot Christopher , Samaha Heba , Seaman Steven , Dobrolecki Lacey , Salsman Vita S. , Oo Htoo Zarni , Bielamowicz Kevin , Landi Daniel , Rainusso Nino , Hicks John , Powell Suzanne , Baker Matthew L. , Wels Winfried S. , Koch Joachim , Sorensen Poul H. , Deneen Benjamin , Ellis Matthew J. , Lewis Michael T. , Hegde Meenakshi , Fletcher Bradley S. , St. Croix Brad , Ahmed Nabil
Published: March 2023

L2 CAR T cells provide a survival advantage and disrupt vessels and tumor architecture in TNBC xenografts .
Figure S3 from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Authors: Byrd Tiara T. , Fousek Kristen , Pignata Antonella , Szot Christopher , Samaha Heba , Seaman Steven , Dobrolecki Lacey , Salsman Vita S. , Oo Htoo Zarni , Bielamowicz Kevin , Landi Daniel , Rainusso Nino , Hicks John , Powell Suzanne , Baker Matthew L. , Wels Winfried S. , Koch Joachim , Sorensen Poul H. , Deneen Benjamin , Ellis Matthew J. , Lewis Michael T. , Hegde Meenakshi , Fletcher Bradley S. , St. Croix Brad , Ahmed Nabil
Published: March 2023

L2 2G and L2 3G CAR T cell normalization and functional testing.
Supplementary Figure S1-S6 from ER Stress Signaling Promotes the Survival of Cancer “Persister Cells” Tolerant to EGFR Tyrosine Kinase Inhibitors
Authors: Terai Hideki , Kitajima Shunsuke , Potter Danielle S. , Matsui Yusuke , Quiceno Laura Gutierrez , Chen Ting , Kim Tae-jung , Rusan Maria , Thai Tran C. , Piccioni Federica , Donovan Katherine A. , Kwiatkowski Nicholas , Hinohara Kunihiko , Wei Guo , Gray Nathanael S. , Fischer Eric S. , Wong Kwok-Kin , Shimamura Teppei , Letai Anthony , Hammerman Peter S. , Barbie David A.
Published: March 2023

Figure S1 Preparation experiments for CRIPSR screening. Figure S2 Quality control of the result of CRISPR screening. Figure S3 Validation experiments with PC9 or HCC827 cells transduced sgRNAs targeting ufmylation. Figure S4 ER stress pathway response involve in the phenotypic change of the PC9 cells in the abcense of ufmylation. Figure S5 Inflammation pathway activation affect the status of cancer cells through modifying the apoptosis pathway. Figure S6 Bcl-xL dependency in the cells with increased ER stress
Supplementary Information from IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma
Authors: Cheng Bowie Y. , Lau Eunice Y. , Leung Hoi-Wing , Leung Carmen Oi-Ning , Ho Nicole P. , Gurung Shilpa , Cheng Lily K. , Lin Chi Ho , Lo Regina Cheuk-Lam , Ma Stephanie , Ng Irene Oi-Lin , Lee Terence K.
Published: March 2023

Suppl Materials, Figure Legends 1-7 and Tables showing clinico-pathological correlation of endogenous IRAK1, the effect of IRAK1 alternations on tumorigenicity as well as pathway analysis of HCC cells with or without IRAK1 suppressed
Figure S7 from IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma
Authors: Cheng Bowie Y. , Lau Eunice Y. , Leung Hoi-Wing , Leung Carmen Oi-Ning , Ho Nicole P. , Gurung Shilpa , Cheng Lily K. , Lin Chi Ho , Lo Regina Cheuk-Lam , Ma Stephanie , Ng Irene Oi-Lin , Lee Terence K.
Published: March 2023

Putative AP-1 binding site in AKR1B10 promoter region was identified and AP-1 activity was consistently reduced upon knockdown of AKR1B10
Figure S5 from IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma
Authors: Cheng Bowie Y. , Lau Eunice Y. , Leung Hoi-Wing , Leung Carmen Oi-Ning , Ho Nicole P. , Gurung Shilpa , Cheng Lily K. , Lin Chi Ho , Lo Regina Cheuk-Lam , Ma Stephanie , Ng Irene Oi-Lin , Lee Terence K.
Published: March 2023

By qPCR analysis, AKR1B10 was found to be overexpressed in a cohort of 79 HCC patients. AKR1B10 expression was significantly correlated with IRAK1 in our patient cohort as well as the publicly available dataset
Supplemental Fig 4 from Aberrant Phosphorylation of SMAD4 Thr277-Mediated USP9x–SMAD4 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis
Authors: Wu Yong , Yu Xiaoting , Yi Xianghua , Wu Ke , Dwabe Sami , Atefi Mohammad , Elshimali Yahya , Kemp Kevin T. , Bhat Kruttika , Haro Jesse , Sarkissyan Marianna , Vadgama Jaydutt V.
Published: March 2023

Figure S4 Quantification of Western blot analysis (related to Figure 4) (B-G). Data are presented as mean fold increases ({plus minus}SD) in treated groups over basal values from three independent experiments. B, *p<0.01 vs BSA; #p<0.01 PA+AZD vs PA. E, *p<0.01 vs EV/-PA; #p<0.01 vs EV/+PA. F, *p<0.01 vs EV/-TGF-beta-PA; #p<0.05 vs EV/+TGF-beta-PA; G, *p<0.01 vs WT.
Supplemental Fig 3 from Aberrant Phosphorylation of SMAD4 Thr277-Mediated USP9x–SMAD4 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis
Authors: Wu Yong , Yu Xiaoting , Yi Xianghua , Wu Ke , Dwabe Sami , Atefi Mohammad , Elshimali Yahya , Kemp Kevin T. , Bhat Kruttika , Haro Jesse , Sarkissyan Marianna , Vadgama Jaydutt V.
Published: March 2023

Figure S3 FFA promotes TGF-beta-induced migration by activating ERK and USP9x, Related to Figure 3. A, BT549 cells were plated in Ibidi culture insert dishes (Madison, WI). Cells were cultured in complete medium to 80% confluence, inserts were removed to create a gap and cells were then incubated with BSA, PA, PA plus AZD6244 or WP1130 in the absence or presence of TGF-beta1. Migrating cells were photographed under a phase contrast microscope. B, The percentage of the wound closed was quantified from three independent replicates and is expressed as mean {plus minus} SD. *p<0.05 vs BSA/TGF-beta; #p<0.05 vs PA/TGF-beta.
Supplemental Fig 2 from Aberrant Phosphorylation of SMAD4 Thr277-Mediated USP9x–SMAD4 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis
Authors: Wu Yong , Yu Xiaoting , Yi Xianghua , Wu Ke , Dwabe Sami , Atefi Mohammad , Elshimali Yahya , Kemp Kevin T. , Bhat Kruttika , Haro Jesse , Sarkissyan Marianna , Vadgama Jaydutt V.
Published: March 2023

Figure S2 A, ERK activation is responsible for FFA promotion of TGF-beta-induced inhibition of SMAD4 monoubiquitination, Related to Figure 2. MDA-MB-231 cells were treated with BSA (vehicle) or PA in the presence or absence of AZD6244 or WP1130 for 4 h followed by treatment with or without 3 ng/ml of TGF-beta for another 4 h. Nuclear extracts were made and SMAD4 monoubiquitination was detected. The blot is a representative of 3 blots from 3 independent experiments. *P<0.01 vs control; #P<0.05, PA vs BSA; $P<0.01, PA+AZD vs PA, PA+WP vs PA). B, ERK activation is responsible for FFA promotion of TGF-beta-induced nuclear SAMD4 retention, Related to Figure 2. MDA-MB-231 cells were treated with 3 ng/ml of TGF-beta in the presence or absence of PA, AZD6244 or WP1130 for the times shown and processed for immunofluorescence with anti-SMAD4 antibody. The same cells were also stained with DAPI to visualize nuclei. Intensity of nuclear SMAD4 among these cells was quantified with Image-Pro Plus 6.0 software. The percentages of nuclear SMAD4 levels illustrated at the lower panel represent the mean of three independent experiments, and error bars indicate the SD.
Figure S1 from IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma
Authors: Cheng Bowie Y. , Lau Eunice Y. , Leung Hoi-Wing , Leung Carmen Oi-Ning , Ho Nicole P. , Gurung Shilpa , Cheng Lily K. , Lin Chi Ho , Lo Regina Cheuk-Lam , Ma Stephanie , Ng Irene Oi-Lin , Lee Terence K.
Published: March 2023

RNA sequencing data analysis shows genetic alternations of Toll-like receptor (TLR)/Interleukin-1 receptor (IL1R) mediated signaling in which IRAK1, a serine/threonine kinase, was found to be mostly upregulated
supplementary tables from Loss of NDRG2 Expression Confers Oral Squamous Cell Carcinoma with Enhanced Metastatic Potential
Authors: Tamura Tomohiro , Ichikawa Tomonaga , Nakahata Shingo , Kondo Yudai , Tagawa Yuri , Yamamoto Koji , Nagai Kentaro , Baba Takashi , Yamaguchi Ryoji , Futakuchi Mitsuru , Yamashita Yoshihiro , Morishita Kazuhiro
Published: March 2023

supplementary tables: Supplemental Table 1. Expression rates of immunohistochemical staining of NDRG2 versus p-Akt or p-PTEN in tumors from OSCC patients. Supplementary table related to Figure 1; Supplemental Table 2. Incidence of tumour formation in the tongue of Ndrg2-deficient mice treated with 4-NQO for 16 weeks. Supplementary table related to Figure 2; Supplemental Table 3. Frequency of SCC (squamous cell carcinoma) tumour formation in the tongue of Ndrg2-deficient mice treated with 4-NQO for 16 weeks. Supplementary table related to Figure 2; Supplemental Table 4. Incidence of tumour formation in wild type and Ndrg2-deficient mice after treatment with 4-NQO for 30 weeks. Supplementary table related to Figure 3; Supplemental Table 5. Incidence of tumour development in wild-type and Ndrg2-deficient mice treated with 4-NQO for 30 weeks. Supplementary table related to Figure 3; Supplemental Table 6. Comparison of the frequency of cervical lymph node metastasis between wild-type control and Ndrg2-deficient mice. Supplementary table related to Figure 3.
Supplemental materials and methods from Loss of NDRG2 Expression Confers Oral Squamous Cell Carcinoma with Enhanced Metastatic Potential
Authors: Tamura Tomohiro , Ichikawa Tomonaga , Nakahata Shingo , Kondo Yudai , Tagawa Yuri , Yamamoto Koji , Nagai Kentaro , Baba Takashi , Yamaguchi Ryoji , Futakuchi Mitsuru , Yamashita Yoshihiro , Morishita Kazuhiro
Published: March 2023

Sequences of the primers for Reverse-transcription polymerase chain reaction (RT-PCR) and Quantitative real-time PCR analysis
Supplementary Text from miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma
Authors: Díaz-Martínez Marta , Benito-Jardón Lucía , Alonso Lola , Koetz-Ploch Lisa , Hernando Eva , Teixidó Joaquin
Published: March 2023

Supplementary materials and figure legends
Supplementary Table 2 from miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma
Authors: Díaz-Martínez Marta , Benito-Jardón Lucía , Alonso Lola , Koetz-Ploch Lisa , Hernando Eva , Teixidó Joaquin
Published: March 2023

List of miRNAs showing highest differential expression between A375-VR and parental A375 cells
Supplementary Table 1 from miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma
Authors: Díaz-Martínez Marta , Benito-Jardón Lucía , Alonso Lola , Koetz-Ploch Lisa , Hernando Eva , Teixidó Joaquin
Published: March 2023

List of siRNAs and oligonucleotides used in qPCR experiments.
Supplemental figure legends from Loss of NDRG2 Expression Confers Oral Squamous Cell Carcinoma with Enhanced Metastatic Potential
Authors: Tamura Tomohiro , Ichikawa Tomonaga , Nakahata Shingo , Kondo Yudai , Tagawa Yuri , Yamamoto Koji , Nagai Kentaro , Baba Takashi , Yamaguchi Ryoji , Futakuchi Mitsuru , Yamashita Yoshihiro , Morishita Kazuhiro
Published: March 2023

Supplemental figure legends
Supplementary Figures from miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma
Authors: Díaz-Martínez Marta , Benito-Jardón Lucía , Alonso Lola , Koetz-Ploch Lisa , Hernando Eva , Teixidó Joaquin
Published: March 2023

Figure S1. Characterization of vemurafenib-resistant melanoma cells. Figure S2. Sensitivity of A375-VR cells to other inhibitors of the MAP kinase pathway. Figure S3. Characterization of invasive properties ofA375-VR cells and sensitivity to a Rac inhibitor. Figure S4. Characterization of miRNA expression in melanoma cells resistant to BRAF and MEK inhibitors, and in foreskin melanocytes. Figure S5. Overexpression or silencing of miRNAs in A375, SK-Mel 28 and A375-VR cells. Figure S6. Role of miR-204-5p, miR-211-5p and miR-140-3p in melanoma resistance to MAP kinase inhibitors and to AKT blockers. Figure S7. miRNA role in VMF resistance in BRAF wild type cells. Figure S8. Analyses of miRNA target expression in cells overexpressing miR-204-5p and miR-211-5p and in A375-VR cells.
Table S1, S2, S3, S4 from Bivalent Chromatin Domains in Glioblastoma Reveal a Subtype-Specific Signature of Glioma Stem Cells
Authors: Hall Amelia Weber , Battenhouse Anna M. , Shivram Haridha , Morris Adam R. , Cowperthwaite Matthew C. , Shpak Max , Iyer Vishwanath R.
Published: March 2023

Table S1: Output of ChromHMM and color key. Table S2: Enhancer counts. Table S3: Enhancer distribution. Table S4: Bivalent region counts.
File S5 from Bivalent Chromatin Domains in Glioblastoma Reveal a Subtype-Specific Signature of Glioma Stem Cells
Authors: Hall Amelia Weber , Battenhouse Anna M. , Shivram Haridha , Morris Adam R. , Cowperthwaite Matthew C. , Shpak Max , Iyer Vishwanath R.
Published: March 2023

Bivalent regions that are present in at least 8 tumors, and the gene they are located within or proximal to
Supplementary Table 2 from Cyp24a1 Attenuation Limits Progression of BrafV600E-Induced Papillary Thyroid Cancer Cells and Sensitizes Them to BRAFV600E Inhibitor PLX4720
Authors: Zou Minjing , Baitei Essa Y. , BinEssa Huda A. , Al-Mohanna Futwan A. , Parhar Ranjit S. , St-Arnaud René , Kimura Shioko , Pritchard Catrin , Alzahrani Ali S. , Assiri Abdullah M. , Meyer Brian F. , Shi Yufei
Published: March 2023

Supplementary Table 2. Differentially expressed vitamin D responsive genes in BVECyp24a1-wt and BVECyp24a1-null cells
File S4 from Bivalent Chromatin Domains in Glioblastoma Reveal a Subtype-Specific Signature of Glioma Stem Cells
Authors: Hall Amelia Weber , Battenhouse Anna M. , Shivram Haridha , Morris Adam R. , Cowperthwaite Matthew C. , Shpak Max , Iyer Vishwanath R.
Published: March 2023

Bivalent normalized expression in FPKM of the 840 genes identified by DAVID in Fig. 6A.
Supplementary Table 1 from Cyp24a1 Attenuation Limits Progression of BrafV600E-Induced Papillary Thyroid Cancer Cells and Sensitizes Them to BRAFV600E Inhibitor PLX4720
Authors: Zou Minjing , Baitei Essa Y. , BinEssa Huda A. , Al-Mohanna Futwan A. , Parhar Ranjit S. , St-Arnaud René , Kimura Shioko , Pritchard Catrin , Alzahrani Ali S. , Assiri Abdullah M. , Meyer Brian F. , Shi Yufei
Published: March 2023

Supplementary Table 1. Primer sequences for qPCR
File S3 from Bivalent Chromatin Domains in Glioblastoma Reveal a Subtype-Specific Signature of Glioma Stem Cells
Authors: Hall Amelia Weber , Battenhouse Anna M. , Shivram Haridha , Morris Adam R. , Cowperthwaite Matthew C. , Shpak Max , Iyer Vishwanath R.
Published: March 2023

Enhancer normalized expression in FPKM of the 307 genes identified by DAVID in Fig. 5A.
File S2 from Bivalent Chromatin Domains in Glioblastoma Reveal a Subtype-Specific Signature of Glioma Stem Cells
Authors: Hall Amelia Weber , Battenhouse Anna M. , Shivram Haridha , Morris Adam R. , Cowperthwaite Matthew C. , Shpak Max , Iyer Vishwanath R.
Published: March 2023

Merged Tuxedo Suite output for tumor data, combining the cuffdiff and cuffnorm tables by unique ENSEMBL identifier
Supplementary Tables 1 and 2 from Oncogenic Effects of High MAPK Activity in Colorectal Cancer Mark Progenitor Cells and Persist Irrespective of RAS Mutations
Authors: Blaj Cristina , Schmidt Eva Marina , Lamprecht Sebastian , Hermeking Heiko , Jung Andreas , Kirchner Thomas , Horst David
Published: March 2023

Supplementary Table S1: Colorectal cancer case characteristics. Supplementary Table S2: Antibody details and concentrations for immunoblotting, immune fluorescence and immunohistochemistry.
Figure S1, S2, S3, S4, S5, S6, S7, S8, S9 from Bivalent Chromatin Domains in Glioblastoma Reveal a Subtype-Specific Signature of Glioma Stem Cells
Authors: Hall Amelia Weber , Battenhouse Anna M. , Shivram Haridha , Morris Adam R. , Cowperthwaite Matthew C. , Shpak Max , Iyer Vishwanath R.
Published: March 2023

Figure S1: Copy number alterations in GBM tumor genomes. Figure S2: Clustering of primary GBM tumors relative to GBM-derived cell lines. Figure S3: Gene expression over all 21 chromatin states in GBM tumors. Figure S4: Methylation over all identified chromatin states, over the 11 tumors analyzed in this study. Figure S5: 5hmC signal over enhancers, enhancer distance to genes, average expression of enhancer-associated genes by tumor. Figure S6: Sequence motifs in enhancers. Figure S7: Gene expression and chromatin signal for frequently bivalent domains and associated genes. Figure S8: Histone mark profiles over the HOXB locus, comparing GBM data with Roadmap Epigenomics brain data. Figure S9: Bivalent regions in T98G cells and their overlap with bivalent regions identified in at least 8 tumors.
Figure S7 from Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments
Authors: Cauwels Anje , Van Lint Sandra , Paul Franciane , Garcin Geneviève , De Koker Stefaan , Van Parys Alexander , Wueest Thomas , Gerlo Sarah , Van der Heyden José , Bordat Yann , Catteeuw Dominiek , Rogge Elke , Verhee Annick , Vandekerckhove Bart , Kley Niko , Uzé Gilles , Tavernier Jan
Published: March 2023

Combination treatments of orthotopic 4T1 tumors with Clec9A-mAFN do not cause toxicity.
Supplemental Figure Legends from Cancer-Associated Fibroblasts Drive Glycolysis in a Targetable Signaling Loop Implicated in Head and Neck Squamous Cell Carcinoma Progression
Authors: Kumar Dhruv , New Jacob , Vishwakarma Vikalp , Joshi Radhika , Enders Jonathan , Lin Fangchen , Dasari Sumana , Gutierrez Wade R. , Leef George , Ponnurangam Sivapriya , Chavan Hemantkumar , Ganaden Lydia , Thornton Mackenzie M. , Dai Hongying , Tawfik Ossama , Straub Jeffrey , Shnayder Yelizaveta , Kakarala Kiran , Tsue Terance Ted , Girod Douglas A. , Van Houten Bennett , Anant Shrikant , Krishnamurthy Partha , Thomas Sufi Mary
Published: March 2023

Legends for all supplemental figures
Figure S6 from Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments
Authors: Cauwels Anje , Van Lint Sandra , Paul Franciane , Garcin Geneviève , De Koker Stefaan , Van Parys Alexander , Wueest Thomas , Gerlo Sarah , Van der Heyden José , Bordat Yann , Catteeuw Dominiek , Rogge Elke , Verhee Annick , Vandekerckhove Bart , Kley Niko , Uzé Gilles , Tavernier Jan
Published: March 2023

Combination treatments of s.c. 4T1 tumors with Clec9A-mAFN do not cause toxicity.
Figure S4 from Cancer-Associated Fibroblasts Drive Glycolysis in a Targetable Signaling Loop Implicated in Head and Neck Squamous Cell Carcinoma Progression
Authors: Kumar Dhruv , New Jacob , Vishwakarma Vikalp , Joshi Radhika , Enders Jonathan , Lin Fangchen , Dasari Sumana , Gutierrez Wade R. , Leef George , Ponnurangam Sivapriya , Chavan Hemantkumar , Ganaden Lydia , Thornton Mackenzie M. , Dai Hongying , Tawfik Ossama , Straub Jeffrey , Shnayder Yelizaveta , Kakarala Kiran , Tsue Terance Ted , Girod Douglas A. , Van Houten Bennett , Anant Shrikant , Krishnamurthy Partha , Thomas Sufi Mary
Published: March 2023

Combination of AZD-4547 and PF-02341066 indicates potentiated effect in admixed cultures but not in HNSCC only inoculated tumors.
Figure S5 from Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments
Authors: Cauwels Anje , Van Lint Sandra , Paul Franciane , Garcin Geneviève , De Koker Stefaan , Van Parys Alexander , Wueest Thomas , Gerlo Sarah , Van der Heyden José , Bordat Yann , Catteeuw Dominiek , Rogge Elke , Verhee Annick , Vandekerckhove Bart , Kley Niko , Uzé Gilles , Tavernier Jan
Published: March 2023

Combining checkpoint inhibition with Clec9A-mAFN does not cause toxicity.
Figure S4 from Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments
Authors: Cauwels Anje , Van Lint Sandra , Paul Franciane , Garcin Geneviève , De Koker Stefaan , Van Parys Alexander , Wueest Thomas , Gerlo Sarah , Van der Heyden José , Bordat Yann , Catteeuw Dominiek , Rogge Elke , Verhee Annick , Vandekerckhove Bart , Kley Niko , Uzé Gilles , Tavernier Jan
Published: March 2023

Combination treatments of B16 tumors with Clec9A-mAFN do not cause toxicity, in contrast to combinations with WT mIFN.
Figure S2 from Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments
Authors: Cauwels Anje , Van Lint Sandra , Paul Franciane , Garcin Geneviève , De Koker Stefaan , Van Parys Alexander , Wueest Thomas , Gerlo Sarah , Van der Heyden José , Bordat Yann , Catteeuw Dominiek , Rogge Elke , Verhee Annick , Vandekerckhove Bart , Kley Niko , Uzé Gilles , Tavernier Jan
Published: March 2023

Low dose WT mIFN cannot prevent tumor growth, even when targeted to the tumor as an immunocytokine.
Figure S1 from Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments
Authors: Cauwels Anje , Van Lint Sandra , Paul Franciane , Garcin Geneviève , De Koker Stefaan , Van Parys Alexander , Wueest Thomas , Gerlo Sarah , Van der Heyden José , Bordat Yann , Catteeuw Dominiek , Rogge Elke , Verhee Annick , Vandekerckhove Bart , Kley Niko , Uzé Gilles , Tavernier Jan
Published: March 2023

Clec9A-AcTaferon specifically induces IFN signaling signature in CD11c+ CD8+ DC.
Supplemental Tables from High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis
Authors: Hartmaier Ryan J. , Albacker Lee A. , Chmielecki Juliann , Bailey Mark , He Jie , Goldberg Michael E. , Ramkissoon Shakti , Suh James , Elvin Julia A. , Chiacchia Samuel , Frampton Garrett M. , Ross Jeffrey S. , Miller Vincent , Stephens Philip J. , Lipson Doron
Published: March 2023

This file contains supplemental tables S1-S7. The data contained are as follows: (Table S1) Gene lists on the FoundationOne assay, (Table S2) Sample counts per disease, (Table S3) Foundation Medicine sample counts compared to TCGA sample counts, (Table S4) Genes with altered frequencies between local and metastatic disease, (Table S5) Merged MutationAssessor and PolyPhen-2 outputs, (Table S6) Enrichment of NOTCH1 alterations across diseases, (Table S7) Curated list of tumor suppressor genes on the FoundationOne assay.
Supplemental Table 1-3 from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion
Authors: Jiao Xuanmao , Velasco-Velázquez Marco A. , Wang Min , Li Zhiping , Rui Hallgeir , Peck Amy R. , Korkola James E. , Chen Xuelian , Xu Shaohua , DuHadaway James B. , Guerrero-Rodriguez Sandra , Addya Sankar , Sicoli Daniela , Mu Zhaomei , Zhang Gang , Stucky Andres , Zhang Xi , Cristofanilli Massimo , Fatatis Alessandro , Gray Joe W. , Zhong Jiang F. , Prendergast George C. , Pestell Richard G.
Published: March 2023

Supplemental table 1 and 2 is the clinical characteristics of patients analyzed in figure 1B. Supplemental table 3 is the GR50 of breast cancer cell lines treated with Doxorubicin with the addition of either Maraviroc or Vicriviroc.
Supplemental Figures from High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis
Authors: Hartmaier Ryan J. , Albacker Lee A. , Chmielecki Juliann , Bailey Mark , He Jie , Goldberg Michael E. , Ramkissoon Shakti , Suh James , Elvin Julia A. , Chiacchia Samuel , Frampton Garrett M. , Ross Jeffrey S. , Miller Vincent , Stephens Philip J. , Lipson Doron
Published: March 2023

This file contains: cellularity distribution, exon coverage distribution, variant filtering flow chart, detailed disease distributions, FMvTCGA long tail plots by local/metastatic disease, local disease versus plural fluid in FM lung adeno, adenoid cystic carcinoma tile plot, summary of known fusions observed in novel diseases, ERBB2 tile plot in cervical cancers, TCGA MET CN to expression correlation, tile plot of AKT1 E17K colorectal tumors, and distribution of alterations in tumor suppressor genes.
Supplemental Figure 1-11 from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion
Authors: Jiao Xuanmao , Velasco-Velázquez Marco A. , Wang Min , Li Zhiping , Rui Hallgeir , Peck Amy R. , Korkola James E. , Chen Xuelian , Xu Shaohua , DuHadaway James B. , Guerrero-Rodriguez Sandra , Addya Sankar , Sicoli Daniela , Mu Zhaomei , Zhang Gang , Stucky Andres , Zhang Xi , Cristofanilli Massimo , Fatatis Alessandro , Gray Joe W. , Zhong Jiang F. , Prendergast George C. , Pestell Richard G.
Published: March 2023

Supplemental figure 1-11 which include: (1) High resolution image of figure 1A. (2) Supplemental data for the relation between CCR5+ cells and breast cancer stem cells. (3) In vivo tumor formation of CCR5+ vs CCR5- cells. (4) In vivo tumor formation of CCR5 overexpression cells vs vector control cells. (5) Gene expression profile of CCR5+ vs CCR5- cells. (6) The effects of CCR5 on DNA damage repair in MDA-MB-231 cells. (7) A schematic representation of the DNA damage signaling pathways, with target genes enriched in CCR5+ cells. (8) The effects of CCR5 on DNA damage repair based on DNA damage repair reporter assays. (9) The functional synergy of cell killing between CCR5 inhibitors and Doxorubicin. (10) Single cell RNAseq of CCR5+ vs. CCR5- SUM-159 cells. (11) Enrichment of CCR5+ cells in doxorubicin resistant cells.
Legends of Supplemental Figure 1-11 from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion
Authors: Jiao Xuanmao , Velasco-Velázquez Marco A. , Wang Min , Li Zhiping , Rui Hallgeir , Peck Amy R. , Korkola James E. , Chen Xuelian , Xu Shaohua , DuHadaway James B. , Guerrero-Rodriguez Sandra , Addya Sankar , Sicoli Daniela , Mu Zhaomei , Zhang Gang , Stucky Andres , Zhang Xi , Cristofanilli Massimo , Fatatis Alessandro , Gray Joe W. , Zhong Jiang F. , Prendergast George C. , Pestell Richard G.
Published: March 2023

The figure legends of Supplemental figure 1-11 which include: (1) High resolution image of figure 1A. (2) Supplemental data for the relation between CCR5+ cells and breast cancer stem cells. (3) In vivo tumor formation of CCR5+ vs CCR5- cells. (4) In vivo tumor formation of CCR5 overexpression cells vs vector control cells. (5) Gene expression profile of CCR5+ vs CCR5- cells. (6) The effects of CCR5 on DNA damage repair in MDA-MB-231 cells. (7) A schematic representation of the DNA damage signaling pathways, with target genes enriched in CCR5+ cells. (8) The effects of CCR5 on DNA damage repair based on DNA damage repair reporter assays. (9) The functional synergy of cell killing between CCR5 inhibitors and Doxorubicin. (10) Single cell RNAseq of CCR5+ vs. CCR5- SUM-159 cells. (11) Enrichment of CCR5+ cells in doxorubicin resistant cells.
Sup Fig Legends from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
Authors: Brighton Hailey E. , Angus Steven P. , Bo Tao , Roques Jose , Tagliatela Alicia C. , Darr David B. , Karagoz Kubra , Sciaky Noah , Gatza Michael L. , Sharpless Norman E. , Johnson Gary L. , Bear James E.
Published: March 2023

Sup Fig Legends
Supplementary Tables S1-S5 from LNMICC Promotes Nodal Metastasis of Cervical Cancer by Reprogramming Fatty Acid Metabolism
Authors: Shang Chunliang , Wang Wei , Liao Yuandong , Chen Yili , Liu Tianyu , Du Qiqiao , Huang Jiaming , Liang Yanchun , Liu Junxiu , Zhao Yunhe , Guo Luyan , Hu Zheng , Yao Shuzhong
Published: March 2023

Supplementary Tabless show LNMICC was independent prognostic factor for the OS of cervical cancer patients and a high-risk factor for pelvic LN metastasis.
Supplementary Figures S1-S7 from LNMICC Promotes Nodal Metastasis of Cervical Cancer by Reprogramming Fatty Acid Metabolism
Authors: Shang Chunliang , Wang Wei , Liao Yuandong , Chen Yili , Liu Tianyu , Du Qiqiao , Huang Jiaming , Liang Yanchun , Liu Junxiu , Zhao Yunhe , Guo Luyan , Hu Zheng , Yao Shuzhong
Published: March 2023

Supplementary Figures show LNMICC promotes metastasis though FABP5-mediated FA metabolism in vitro, which is Suppressed by miR190.
Sup Fig 7 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
Authors: Brighton Hailey E. , Angus Steven P. , Bo Tao , Roques Jose , Tagliatela Alicia C. , Darr David B. , Karagoz Kubra , Sciaky Noah , Gatza Michael L. , Sharpless Norman E. , Johnson Gary L. , Bear James E.
Published: March 2023

Kinome and transcriptome responses to combined BRAF and MEK inhibition in murine tumors, patient samples, and human cell lines
Supplementary Tables from Sodium Channel Subunit SCNN1B Suppresses Gastric Cancer Growth and Metastasis via GRP78 Degradation
Authors: Qian Yun , Wong Chi Chun , Xu Jiaying , Chen Huarong , Zhang Yanquan , Kang Wei , Wang Hua , Zhang Li , Li Weilin , Chu Eagle S.H. , Go Minnie Y.Y. , Chiu Philip W.Y. , Ng Enders K.W. , Chan Francis K.L. , Sung Joseph J.Y. , Si Jianmin , Yu Jun
Published: March 2023

Table S1-S6
Sup Fig 5 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
Authors: Brighton Hailey E. , Angus Steven P. , Bo Tao , Roques Jose , Tagliatela Alicia C. , Darr David B. , Karagoz Kubra , Sciaky Noah , Gatza Michael L. , Sharpless Norman E. , Johnson Gary L. , Bear James E.
Published: March 2023

Expanded detail on MIB MS experiment
Supplementary Figures from Sodium Channel Subunit SCNN1B Suppresses Gastric Cancer Growth and Metastasis via GRP78 Degradation
Authors: Qian Yun , Wong Chi Chun , Xu Jiaying , Chen Huarong , Zhang Yanquan , Kang Wei , Wang Hua , Zhang Li , Li Weilin , Chu Eagle S.H. , Go Minnie Y.Y. , Chiu Philip W.Y. , Ng Enders K.W. , Chan Francis K.L. , Sung Joseph J.Y. , Si Jianmin , Yu Jun
Published: March 2023

Figure S1-S8
Sup Fig 4 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
Authors: Brighton Hailey E. , Angus Steven P. , Bo Tao , Roques Jose , Tagliatela Alicia C. , Darr David B. , Karagoz Kubra , Sciaky Noah , Gatza Michael L. , Sharpless Norman E. , Johnson Gary L. , Bear James E.
Published: March 2023

MEKi Experiment Overview
Sup Fig 3 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
Authors: Brighton Hailey E. , Angus Steven P. , Bo Tao , Roques Jose , Tagliatela Alicia C. , Darr David B. , Karagoz Kubra , Sciaky Noah , Gatza Michael L. , Sharpless Norman E. , Johnson Gary L. , Bear James E.
Published: March 2023

Structural reorganization and amelanotic intratumoral nests are evident in persistent melanoma on MEKi.
Supplemental Data from NRAS-Mutated Rhabdomyosarcoma Cells Are Vulnerable to Mitochondrial Apoptosis Induced by Coinhibition of MEK and PI3Kα
Authors: Dolgikh Nadezda , Hugle Manuela , Vogler Meike , Fulda Simone
Published: March 2023

Suppl. Figure 1. NRAS depletion reduces cell viability of NRAS mutated RMS cells. Suppl. Figure 2. MEK162 and BYL719 synergize to induce apoptosis in NRAS-mutated RMS cells. Suppl. Figure 3. MEK162 and BYL719 synergize to induce apoptosis in NRAS-mutated neuroblastoma and leukemia cell lines. Suppl. Figure 4. MEK162/BYL719-induced caspase-dependent apoptosis. Suppl. Figure 5. Effect of NRAS knockdown on RAF/MEK/ERK and PI3K/AKT/mTOR signaling. Suppl. Figure 6. Effect of MEK162/BYL719 cotreatment in RAS wildtype RMS cells. Suppl. Figure 7. NRAS knockdown induces BIM and BMF mRNA expression. Suppl. Figure 8. NRAS silencing is synthetic lethal with MCL-1 inhibition. Suppl. Figure 9. Expression of BIM, BMF and MCL-1 in RMS cell lines. Suppl. Figure 10. MEK162/BYL719 cotreatment increases the binding of BMF and BIM to antiapoptotic BCL-2 proteins. Suppl. Figure 11. MEK162 and BYL719 cooperate to trigger BAX and BAK activation. Suppl. Table 1. List of primers Suppl. Table 2. Summary of identified RAS mutations in RMS cell lines. Suppl. Table 3. Synergistic induction of apoptosis by MEK162 and BYL719.
Supplementary Figure 8 from Atypical G Protein β5 Promotes Cardiac Oxidative Stress, Apoptosis, and Fibrotic Remodeling in Response to Multiple Cancer Chemotherapeutics
Authors: Chakraborti Sreemoyee , Pramanick Arnab , Saha Sudipta , Roy Somnath Singha , Chaudhuri Arnab Ray , Das Madhusudan , Ghosh Sujoy , Stewart Adele , Maity Biswanath
Published: March 2023

Figure S8. Gβ5 promotes pathological myocyte-fibroblast crosstalk activated upon chemotherapeutic drug exposure.
Supplementary Figure 7 from Atypical G Protein β5 Promotes Cardiac Oxidative Stress, Apoptosis, and Fibrotic Remodeling in Response to Multiple Cancer Chemotherapeutics
Authors: Chakraborti Sreemoyee , Pramanick Arnab , Saha Sudipta , Roy Somnath Singha , Chaudhuri Arnab Ray , Das Madhusudan , Ghosh Sujoy , Stewart Adele , Maity Biswanath
Published: March 2023

Figure S7. p53 knockdown in VCM fails to impact cardiac fibrosis following doxorubicin exposure.
Supplementary Figure 6 from Atypical G Protein β5 Promotes Cardiac Oxidative Stress, Apoptosis, and Fibrotic Remodeling in Response to Multiple Cancer Chemotherapeutics
Authors: Chakraborti Sreemoyee , Pramanick Arnab , Saha Sudipta , Roy Somnath Singha , Chaudhuri Arnab Ray , Das Madhusudan , Ghosh Sujoy , Stewart Adele , Maity Biswanath
Published: March 2023

Figure S6. Gβ5 functions in a pathway with ROS, ATM and CAMKII to promote chemotherapeutic drug-induced cardiomyocyte apoptosis.
Sup Fig 2 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
Authors: Brighton Hailey E. , Angus Steven P. , Bo Tao , Roques Jose , Tagliatela Alicia C. , Darr David B. , Karagoz Kubra , Sciaky Noah , Gatza Michael L. , Sharpless Norman E. , Johnson Gary L. , Bear James E.
Published: March 2023

BRAFV600E and PTEN-loss are required for tumor growth, which is temporally controlled and reproducible at the cell level.
Supplementary material and method from Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3–NANOG Axis
Authors: Oh Se Jin , Cho Hanbyoul , Kim Suhyun , Noh Kyung Hee , Song Kwon-Ho , Lee Hyo-Jung , Woo Seon Rang , Kim Suyeon , Choi Chel Hun , Chung Joon-Yong , Hewitt Stephen M. , Kim Jae-Hoon , Baek Seungki , Lee Kyung-Mi , Yee Cassian , Park Hae-Chul , Kim Tae Woo
Published: March 2023

Cell lines, Western blot (WB) analysis, Flow cytomeray analysis, SUPPLEMENTARY REFERENCES.
Figures S1-S6 from Small-Molecule Inhibition of PD-1 Transcription Is an Effective Alternative to Antibody Blockade in Cancer Therapy
Authors: Taylor Alison , Rothstein David , Rudd Christopher E.
Published: March 2023

GSK-3 inhibition effects on T-cells and anti-tumor responses
Supplementary Figures and Table from Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3–NANOG Axis
Authors: Oh Se Jin , Cho Hanbyoul , Kim Suhyun , Noh Kyung Hee , Song Kwon-Ho , Lee Hyo-Jung , Woo Seon Rang , Kim Suyeon , Choi Chel Hun , Chung Joon-Yong , Hewitt Stephen M. , Kim Jae-Hoon , Baek Seungki , Lee Kyung-Mi , Yee Cassian , Park Hae-Chul , Kim Tae Woo
Published: March 2023

Supplementary Figure 1. SCP3 overexpression induces NANOG-mediated immune resistance and stem-like properties in human cancer cells. Supplementary Figure 2. MHC class I expression and CTL activation capacity of tumor cells are unaffected by SCP3 expression. Supplementary Figure 3. SCP3 expression in tumor cells does not control the viability of CTLs. Supplementary Figure 4. The SCP3 axis is conserved across various human cancer types. Supplementary Figure 5. CDK4/6 inhibitor is more effective than other drugs in SCP3-positive tumor cells. Supplementary Figure 6. Schematic interpretation of therapeutic resistance and tumorigenicity through the SCP3 axis.
Supplementary methods from Autocrine Adenosine Regulates Tumor Polyfunctional CD73+CD4+ Effector T Cells Devoid of Immune Checkpoints
Authors: Gourdin Nicolas , Bossennec Marion , Rodriguez Céline , Vigano Selena , Machon Christelle , Jandus Camilla , Bauché David , Faget Julien , Durand Isabelle , Chopin Nicolas , Tredan Olivier , Marie Julien C. , Dubois Bertrand , Guitton Jérôme , Romero Pedro , Caux Christophe , Ménétrier-Caux Christine
Published: March 2023

Material and methods for the migration assay of CD4 T cells in response to CXCL10 and CCL20.
Table S3 from Antitumor Effects of Blocking Protein Neddylation in T315I-BCR-ABL Leukemia Cells and Leukemia Stem Cells
Authors: Liu Chang , Nie Danian , Li Juan , Du Xin , Lu Yuhong , Li Yangqiu , Zhou Jingfeng , Jin Yanli , Pan Jingxuan
Published: March 2023

Table S3 shows limiting dilution assay of mouse LT-HSCs after drug treatment.
Figure S5 from Autocrine Adenosine Regulates Tumor Polyfunctional CD73+CD4+ Effector T Cells Devoid of Immune Checkpoints
Authors: Gourdin Nicolas , Bossennec Marion , Rodriguez Céline , Vigano Selena , Machon Christelle , Jandus Camilla , Bauché David , Faget Julien , Durand Isabelle , Chopin Nicolas , Tredan Olivier , Marie Julien C. , Dubois Bertrand , Guitton Jérôme , Romero Pedro , Caux Christophe , Ménétrier-Caux Christine
Published: March 2023

Cumulative data of percentages of memory T CD4+ cells, Treg and CD73+CD4+ Teff and cytokine production profile of CD73neg and CD73+ Teff in HD-Blood, and blood and tumors from breast or ovarian patients.
Table S2 from Antitumor Effects of Blocking Protein Neddylation in T315I-BCR-ABL Leukemia Cells and Leukemia Stem Cells
Authors: Liu Chang , Nie Danian , Li Juan , Du Xin , Lu Yuhong , Li Yangqiu , Zhou Jingfeng , Jin Yanli , Pan Jingxuan
Published: March 2023

Table S2 shows characteristics of patients with chronic myelogenous leukemia.
Supplementary Information from Antitumor Effects of Blocking Protein Neddylation in T315I-BCR-ABL Leukemia Cells and Leukemia Stem Cells
Authors: Liu Chang , Nie Danian , Li Juan , Du Xin , Lu Yuhong , Li Yangqiu , Zhou Jingfeng , Jin Yanli , Pan Jingxuan
Published: March 2023

Supplementary Information
Figure S2 from Autocrine Adenosine Regulates Tumor Polyfunctional CD73+CD4+ Effector T Cells Devoid of Immune Checkpoints
Authors: Gourdin Nicolas , Bossennec Marion , Rodriguez Céline , Vigano Selena , Machon Christelle , Jandus Camilla , Bauché David , Faget Julien , Durand Isabelle , Chopin Nicolas , Tredan Olivier , Marie Julien C. , Dubois Bertrand , Guitton Jérôme , Romero Pedro , Caux Christophe , Ménétrier-Caux Christine
Published: March 2023

Impact of rh-ADA on Ado-mediated inhibition of CD73+ or CD73neg CD4+ Teff based on the proliferation marker profiles (Cell Trace Violet or CFSE)
Figure S1 from Autocrine Adenosine Regulates Tumor Polyfunctional CD73+CD4+ Effector T Cells Devoid of Immune Checkpoints
Authors: Gourdin Nicolas , Bossennec Marion , Rodriguez Céline , Vigano Selena , Machon Christelle , Jandus Camilla , Bauché David , Faget Julien , Durand Isabelle , Chopin Nicolas , Tredan Olivier , Marie Julien C. , Dubois Bertrand , Guitton Jérôme , Romero Pedro , Caux Christophe , Ménétrier-Caux Christine
Published: March 2023

Th1.17 characteristics of CD73+ CD4+ Teff based on the expression of CXCR3, CCR6, CRTH2, the migration in response to CXCL10 or CCL20 gradient and the MDR-1-specific Rhodamine 123 exclusion assay
Supplemental Material from Defining Cancer Subpopulations by Adaptive Strategies Rather Than Molecular Properties Provides Novel Insights into Intratumoral Evolution
Authors: Ibrahim-Hashim Arig , Robertson-Tessi Mark , Enriquez-Navas Pedro M. , Damaghi Mehdi , Balagurunathan Yoganand , Wojtkowiak Jonathan W. , Russell Shonagh , Yoonseok Kam , Lloyd Mark C. , Bui Marilyn M. , Brown Joel S. , Anderson Alexander R.A. , Gillies Robert J. , Gatenby Robert A.
Published: March 2023

Supplemental material contains additional details of tumor imaging and mathematical models. Supplemental figures demonstrating results from experimental and computational studies referenced in the manuscript are included
Supplementary Table S1 from Fibrinolytic Enzyme Cotherapy Improves Tumor Perfusion and Therapeutic Efficacy of Anticancer Nanomedicine
Authors: Kirtane Ameya R. , Sadhukha Tanmoy , Kim Hyunjoon , Khanna Vidhi , Koniar Brenda , Panyam Jayanth
Published: March 2023

Physicochemical characterization of paclitaxel nanoparticles.
Figure S6 from The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival
Authors: Shen Jiajia , Li Pengyu , Shao Xuejing , Yang Yang , Liu Xiujun , Feng Min , Yu Qiang , Hu Ronggui , Wang Zhen
Published: March 2023

p53 exerts little effect on RING1 expression and the genetic alterations of p53 and RING1
Figure S4 from The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival
Authors: Shen Jiajia , Li Pengyu , Shao Xuejing , Yang Yang , Liu Xiujun , Feng Min , Yu Qiang , Hu Ronggui , Wang Zhen
Published: March 2023

RING1 deficiency results in partial G1 arrest and p21 induction in the cells harboring wild-type p53, and its growth inhibitory effect is partially rescued by p53 silencing
Supplementary Figure S4 from Fibrinolytic Enzyme Cotherapy Improves Tumor Perfusion and Therapeutic Efficacy of Anticancer Nanomedicine
Authors: Kirtane Ameya R. , Sadhukha Tanmoy , Kim Hyunjoon , Khanna Vidhi , Koniar Brenda , Panyam Jayanth
Published: March 2023

Safety of combination treatment of tPA and paclitaxel nanoparticles.
Figure S3 from The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival
Authors: Shen Jiajia , Li Pengyu , Shao Xuejing , Yang Yang , Liu Xiujun , Feng Min , Yu Qiang , Hu Ronggui , Wang Zhen
Published: March 2023

Interaction of p53 with RING1 is independent of RNF2
Supplementary Figure S3 from Fibrinolytic Enzyme Cotherapy Improves Tumor Perfusion and Therapeutic Efficacy of Anticancer Nanomedicine
Authors: Kirtane Ameya R. , Sadhukha Tanmoy , Kim Hyunjoon , Khanna Vidhi , Koniar Brenda , Panyam Jayanth
Published: March 2023

Effect of tPA on cellular uptake of nanoparticles in B16F10 cells.
Figure S2 from The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival
Authors: Shen Jiajia , Li Pengyu , Shao Xuejing , Yang Yang , Liu Xiujun , Feng Min , Yu Qiang , Hu Ronggui , Wang Zhen
Published: March 2023

RING1 binds to p53 in vivo and in vitro, and affects the ubiqutination level of p53
Supplementary Figure S2 from Fibrinolytic Enzyme Cotherapy Improves Tumor Perfusion and Therapeutic Efficacy of Anticancer Nanomedicine
Authors: Kirtane Ameya R. , Sadhukha Tanmoy , Kim Hyunjoon , Khanna Vidhi , Koniar Brenda , Panyam Jayanth
Published: March 2023

Fibrin(ogen) staining in tumors grown in mice.
Supplementary Figure Legends from Fibrinolytic Enzyme Cotherapy Improves Tumor Perfusion and Therapeutic Efficacy of Anticancer Nanomedicine
Authors: Kirtane Ameya R. , Sadhukha Tanmoy , Kim Hyunjoon , Khanna Vidhi , Koniar Brenda , Panyam Jayanth
Published: March 2023

Legend for Supplementary Figures S1-S7.
Figure S3. from PADI2-Mediated Citrullination Promotes Prostate Cancer Progression
Authors: Wang Lin , Song Guanhua , Zhang Xiang , Feng Tingting , Pan Jihong , Chen Weiwen , Yang Muyi , Bai Xinnuo , Pang Yu , Yu Jindan , Han Jinxiang , Han Bo
Published: March 2023

Enrichment of citrullinated H3R2+R8+R17 and H4R3 on AR target gene. No visible citrullination of H3R2+R8+R17 and H4R3 on AR target gene was observed after treatment with silPADI2 or Cl-amidine.
Supplementary Tables from Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
Authors: Lu Haiquan , Tran Linh , Park Youngrok , Chen Ivan , Lan Jie , Xie Yangyiran , Semenza Gregg L.
Published: March 2023

Tables S1-S5, containing supplementary information for Materials and Methods
Supplementary Figure Legends from Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
Authors: Lu Haiquan , Tran Linh , Park Youngrok , Chen Ivan , Lan Jie , Xie Yangyiran , Semenza Gregg L.
Published: March 2023

Legends for Fig. S1-S6
Figure S3 from Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
Authors: Lu Haiquan , Tran Linh , Park Youngrok , Chen Ivan , Lan Jie , Xie Yangyiran , Semenza Gregg L.
Published: March 2023

HIF-1 activates transcription of the DUSP9, REST and RCOR2 genes.